CVS Health Corp vs Vanguard Total Stock Market Index Fund ETF — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Vanguard Total Stock Market Index Fund ETF trades at $381.34. The key difference: CVS Health Corp pays a 2.78% dividend while Vanguard Total Stock Market Index Fund ETF pays none, and Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, CVS Health Corp nearer its low. Which is the better fit depends on your goals.
| CVS | VTI | |
|---|---|---|
Market Cap | $122.36B | — |
Sector | Health | — |
52-Week High | $110.60 | $381.78 |
52-Week Low | $65.51 | $311.68 |
Enterprise Value | $184.71B | — |
Dividend Yield | 2.78% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
VTI trades at $381.78, up 0.71% with strong bullish momentum indicated by moving averages. The ETF shows institutional accumulation with multiple firms increasing positions in Q2 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength. Recent news highlights VTI's role as a core portfolio holding for long-term investors seeking broad market exposure.
VTI offers diversified US equity exposure with low-cost structure, though recent fee competition from competitors like BBUS presents margin pressure. The ETF's 14.53% 10-year annualized return demonstrates strong historical performance. Key risks include market concentration in large-cap tech and broader economic sensitivity. Analyst sentiment remains positive for long-term investors seeking total market diversification.
Trailing returns across standard periods
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →